rozecoc nerma

10

15

1. Use of methoxymorpholino doxorubicin (MMDX) of formula

15

in the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumour.

2. Use according to claim 1. wherein the liver tumor is a tumor primarily confined to the liver.

3. Use according to claim 2. wherein the tumor primarily confined to the liver is a hepatocellular carcinoma (HCC) or a cholangiocarcinoma.

4. Use according to claim 1. wherein the tumor is a liver metastasis.

5. Use according to any one of the preceeding claims wherein the intrahepatic administration of MMDX is via the hepatic artery.

10

15

30


. Use according to any one of the preceeding claims wherein MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks.

- 5 7. Use according to anyone of claims 1. to 6. wherein MMDX is administered as a 5-10 minute bolus every 8 weeks.
  - 8. Use according to any one of the preceeding claims wherein MMDX is administered with an agent which remains selectively in a liver tumor after its injection through the hepatic artery.
  - 9. Use according to claim 8. wherein the agent is iodized oil.
  - 10. Use according to anyone of the preceeding claims wherein MMDX is administered in a dose ranging from about 100  $mcg/m^2$  to about 1000  $mcg/m^2$ .
- 20 11. Use according to claim 10. wherein MMDX is administered in a dose ranging form about 100  $mcg/m^2$  to about 800  $mcg/m^2$ .
- 12. Use according to claim 11. wherein the dose is 200 mcg/m<sup>2</sup>.
  - 13. A pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery.

5

10

20



15. Use of a pharmaceutical composition according to claim 13. or 14. for the treatment of a liver tumor.

16. Use of a pharmaceutical composition which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery, for the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumor.

17. Use according to claim 16 wherein the agent is iodized oil.

18. A method of treating a human liver tumor which comprises the intrahepatic administration of a therapeutically effective amount of MMDX to a patient in need thereof.

19. A method for reducing MMDX systemic exposure of a patient suffering from a liver cancer which comprises the intrahepatic administration of a therapeutically effective amount of MMDX to said patient.